Vantis Vascular Secures Funding for CrossFast Microcatheter Delivery System Commercialization

December 12, 2024—Vantis Vascular, Inc. announced the closing of $10 million Series B-1 preferred financing, which comes after raising $30 million to date from high net-worth individuals and National Institute of Health grants.

According to Vantis, the funds will be used to initiate the United States commercialization of its CrossFast integrated microcatheter advanced delivery system. The device is commercially available in the United States as part of a limited market release. A full market release is planned for 2025.

The company stated that the CrossFast system is a dual monorail microcatheter advanced delivery system for complex coronary and peripheral interventions. The CrossFast system incorporates an integrated microcatheter with a seamless transition to lower the risk of adverse events during catheter delivery.

Additionally, the CrossFast system is powered by DuoPro interlocking technology, which couples the microcatheter to the outer delivery catheter, allowing the system to be advanced as one unit for enhanced pushability and efficient navigation, noted Vantis.